Clinical Trial Update: CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of bendamustine plus GA101 (obinutuzumab) in relapsed/refractory chronic lymphocytic leukemia with GA101 maintenance for responders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• GA101 (obinutuzumab) (obinutuzumab)

Snippet

Sponsor: Munich Municipal Hospital | Conditions: Chronic Lymphocytic Leucemia | Phase 2 | Status: UNKNOWN